• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALERE SAN DIEGO, INC. INRATIO; PROTHROMBIN TIME TEST

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALERE SAN DIEGO, INC. INRATIO; PROTHROMBIN TIME TEST Back to Search Results
Model Number 100137
Device Problems Nonstandard Device (1420); Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Anemia (1706); Death (1802); Embolism (1829); Transient Ischemic Attack (2109); Collapse (2416)
Event Date 01/05/2014
Event Type  malfunction  
Event Description
The customer's wife called to report potential discrepant inratio inr results and that her husband expired on (b)(6) 2014.The husband's therapeutic range was 2.0 - 2.5.He was reported to be "slightly anemic"; however, no results were provided.The following is a chronological history of the available information.(b)(6) 2014: inratio=2.2, (b)(6) 2014: inratio=2.2, (b)(6) 2014: inratio=1.8, (b)(6) 2014: inratio=2.4, (b)(6) 2014: inratio=1.6, (b)(6) 2014: inratio=2.1, (b)(6) 2014: hospitalized after getting out of bed and collapsing.There were no laboratory inr results provided at the time of hospitalization.The wife reported that the medical staff told her the inr was "high".(b)(6) 2014: discharged from hospital.Customer was switched from generic warfarin 4-5mg daily to coumadin 4-5mg daily.(b)(6) 2014: inratio=1.9, (b)(6) 2014: inratio=2.3, (b)(6) 2014: inratio=2.0, (b)(6) 2014: inratio=2.5, (b)(6) 2014: inratio=2.1, (b)(6) 2014: the customer expired.Per death certificate, the cause of death, was complications from embolic stroke.There is no information available to suggest that the device caused or contributed to the reported event.This event is conservatively reported due to alleged deficiency that cannot be substantiated without access to additional data or results.Multiple attempts were made to obtain additional information; however, no further information was provided.
 
Manufacturer Narrative
Investigation/conclusion: the customer's wife provided multiple inratio inr results without providing laboratory reference results.The monitor and inratio test strips associated with the complaint were returned for investigation.The customer's complaint of discrepant results was not replicated with the returned monitor and strips using in-house donors.A review of the manufacturing records for the lot did not uncover any non-conformances and the lot met release specification.The monitor's memory was reviewed.The impedance curve for the inratio inr result of 2.1 from (b)(6) 2014 was retrieved.The impedance curve was analyzed statistically to determine if it contained a weak slope change.The impedance curve associated with the result of 2.1 from (b)(6) 2014 exhibited a weak slope change.Capa investigation (capa (b)(4)) has determined that impedance curves with weak slope change can cause discrepant results.The capa investigation has also determined that certain patient conditions (e.G.Low hematocrit, elevated plasma proteins) can contribute to weak slope change impedance curves.The customer reported that the patient was "slightly" anemic but a hematocrit value was not provided.A notification letter has been sent to customers to inform them of these patient conditions.The patient passed away on (b)(6) 2014 from complications from an embolic stroke ("clot"), which suggests that the patient's inr value may have been lower than the inr value reported on the inratio monitor.The outcome, of embolic stroke, is typically associated with a patient status of under anti-coagulation.The inratio system reported results that showed the patient was within their therapeutic range, and in some cases, below their therapeutic range.These inr results are not inconsistent with a patient status of under anti-coagulation.Because a reference lab result was not provided, we cannot conclude that the inr result of 2.1 (which was associated with a weak slope change curve) was a discrepant result.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INRATIO
Type of Device
PROTHROMBIN TIME TEST
Manufacturer (Section D)
ALERE SAN DIEGO, INC.
9975 summers ridge road
san diego CA 92121
Manufacturer (Section G)
ALERE SAN DIEGO, INC.
9975 summers ridge road
san diego CA 92121
Manufacturer Contact
ya-ling king
9975 summers ridge road
san diego, CA 92121
8588052084
MDR Report Key4667754
MDR Text Key5733912
Report Number2027969-2015-00246
Device Sequence Number1
Product Code GJS
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K020679
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other
Reporter Occupation Patient Family Member or Friend
Remedial Action Recall
Type of Report Initial
Report Date 05/09/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Lay User/Patient
Device Model Number100137
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer09/19/2014
Is the Reporter a Health Professional? No
Initial Date Manufacturer Received 04/01/2015
Initial Date FDA Received04/08/2015
Was Device Evaluated by Manufacturer? Yes
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Removal/Correction NumberZ-0880, 0881, 0882-2015
Patient Sequence Number1
Treatment
WARFARIN 4-5MG DAILY STOPPED APPROX. (B)(6) 2014; PRAZOSIN 1MG DAILY IN LATE AFTERNOON; COUMADIN 4-5MG DAILY; TERAZOSIN 5MG DAILY IN EVENING; IRON EVERY OTHER DAY; INRATIO PT/INR TEST STRIPS 100139, LOT# K318141; SOTALOL 80MG IN AM
Patient Age79 YR
-
-